查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095690

MRI造影劑市場－2026-2032年全球市場預測

MRI Contrast Media Agents Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，MRI造影劑市場規模將達到 2.5276 億美元，複合年成長率為 7.36%。

主要市場統計數據
基準年 2025 1.5366億美元
預計年份：2026年 1.6431億美元
預測年份 2032 2.5276億美元
複合年成長率 (%) 7.36%

磁振造影造影執行摘要

磁振造影造影（MRI）造影劑是一種專門用於增強磁振造影（MRI）組織顯像的影像產品，特別適用於腦部、脊椎、肝臟、乳房、心血管系統、肌肉骨骼系統和腫瘤評估。這個市場受以下因素影響：钆基造影劑的臨床價值、器官特異性配方、對大環和線性螯合劑偏好的變化，以及對腎功能不全患者、孕婦、兒童患者和需要重複成像的患者安全性的日益關注。市場需求與全球疾病負擔密切相關，包括癌症、神經系統疾病、心血管疾病、發炎性疾病和複雜的手術計劃，所有這些都依賴高品質的造影MRI進行病灶表徵、分期、治療進展監測和鑑別診斷。監管機構和放射學專家持續強調合理使用、劑量最佳化、先前暴露史記錄以及腎源性系統性纖維化和钆滯留的風險篩檢。隨著醫療保健系統擴大其對先進影像診斷的獲取途徑，醫院、診斷中心、門診影像網路和專科診所等相關人員正在優先考慮那些能夠提供診斷確定性、安全性證據、可靠供應、工作流程效率以及與最新 MRI 協議相容的造影劑。

磁振造影劑領域的變革性變化

隨著影像學實踐從廣泛使用造影劑轉向精準指導和風險調整給藥，造影劑領域正經歷重大變革。在放射學領域，由於大環钆造影劑相比許多線性造影造影具有更高的動態篩檢，以大環钆造影劑為中心的方案正逐漸標準化。同時，系統性造影腎功能、過敏史、先前造影劑反應以及钆累積暴露量等也正在實施。另一個重大變革是轉向低劑量、標靶成像方案，這得益於高場磁振造影系統、最佳化的脈衝序列和改進的影像重建技術。此外，門診影像、癌症綜合診療路徑、中風和神經血管影像、肝臟病變表徵以及心臟磁振造影應用的擴展，也影響臨床實務中造影劑的應用。同時，隨著醫療機構要求產品符合穩定的供應鏈、透明的品管和藥物安全監測等要求，永續性和採購彈性變得日益重要。因此，MRI造影劑的競爭格局正在不斷演變，不僅包括產品可用性，還包括安全性、證據豐​​富性、方案適應性、法規遵循、包裝效率以及與數位放射線工作流程的整合等因素。

人工智慧對磁振造影造影劑的累積影響

人工智慧 (AI) 透過改進增強造影造影 (MRI) 的規劃、擷取、解讀和審查方式，對整個 MRI造影系統產生了累積影響。 AI 驅動的方案選擇使放射科團隊能夠根據適應症、先前影像、腎功能和病歷選擇合適的造影劑，從而在保持診斷品質的同時減少不必要的造影劑使用。影像重建和去噪演算法能夠以更快的速度擷取 MRI 影像並獲得更清晰的影像，並且在臨床管治框架內檢驗後，可以支援輻射計量感知成像策略。在影像領域，AI 工具可以輔助腫瘤學、神經病學、乳房 X 光攝影、造影心臟影像和造影中的病灶檢測、分割、對比增強量化、乳房攝影評估和時間序列比較。 AI 還可以透過識別不完整的安全記錄、追蹤重複曝光、協助不利事件監測以及簡化造影劑相關檢查的安排來加強營運監管。尤其是在醫療機構需要跨不同掃描儀和患者群體實現可追溯性、監管合規性、可解釋性和臨床檢驗性能的情況下，人工智慧有望提供最大的短期價值，不是取代放射科醫生的判斷，而是作為決策支援和工作流程品質改進的一層。

關於MRI造影劑的關鍵區域性見解

亞太地區的特點是先進診斷影像能力的快速發展、對癌症和心血管疾病篩檢需求的不斷成長，以及對三級醫療和私人診斷網路​​投資的增加。中國、印度、日本、韓國和澳洲在造影造影（MRI）造影劑的使用方面呈現多樣化的模式。北美地區仍然主要以規範化流程主導，安全篩檢、與電子健康記錄的整合以及基於指南的造影劑使用在美國和加拿大的醫院和門診放射科廣泛應用。歐洲的特點是嚴格的藥物安全監測、環境審查和統一的臨床指南，許多醫療機構在其成熟的醫療保健系統中強調使用大環類造影劑、記錄钆暴露情況以及標準化的知情同意流程。在拉丁美洲，隨著主要都市區私人醫療保健覆蓋範圍的擴大，造影MRI在腫瘤學、神經病學和腹部成像中的應用日益增多，但保險報銷的差異和掃描儀分佈不均正在影響其使用。在中東，磁振造影（MRI）技術正在不斷提升，尤其是在高所得的海灣國家，這得益於醫院現代化、醫療旅遊以及腫瘤科、循環系統和神經科等專科中心的建立。非洲的情況則更為複雜，MRI造影劑的應用主要集中在大型都市區醫院和學術機構，但基礎設施的限制、專家的匱乏、對進口的依賴以及經濟負擔仍然是影響其應用的主要因素。

磁振造影劑的主要分組分析

在東協市場，隨著公立和私立醫療系統不斷完善影像基礎設施，增強造影造影（MRI）的應用日益普及，其需求主要集中在腫瘤學、神經影像學、肝膽評估以及都市區診斷中心的興起。海灣合作理事會（GCC）成員國的特點是：對先進醫院的投資、專業影像服務的高利用率，以及對可靠的採購、監管品質標準和高品質診斷流程的強勁需求，這些需求貫穿三級和四級醫療機構。歐盟在MRI造影劑標準化方面發揮核心作用，其透過嚴格的藥品監管、上市後監測、環境風險評估以及基於指南的臨床實踐，確保了安全性文件的一致性。金磚國家（BRICS）的影像成熟度頻譜較大，擁有龐大的患者群體和不斷擴展的三級醫療服務，同時，可負擔性、供應穩定性和先進診斷技術的可及性在當地也日益重要。七國集團（G7）國家普遍擁有成熟的磁振造影（MRI）應用、完善的放射學管治體系、健全的報銷機制，並且高度重視钆在體內的滯留、腎臟安全性以及風險效益評估等方面的證據。北約成員國雖然醫療衛生體系各有不同，但通用共同關注醫療供應鏈的韌性、醫院的緊急準備以及先進的診斷能力，凸顯了對可靠的MRI造影劑採購和標準化安全規程的需求。

主要國家MRI造影劑的發展趨勢

美國在腫瘤學、神經病學、乳房科、心臟病學和肌肉骨骼成像領域，率先採用規範化的造影增強磁振造影技術，這得益於其廣泛的門診影像網路和詳盡的安全文件記錄。在加拿大，主要都市區正在推動先進磁振造影技術的應用，重點在於基於指南的使用、腎功能風險評估以及各省醫療保健系統之間的公平獲取。在墨西哥，造影磁振造影技術正透過私人醫院和診斷連鎖機構推廣，但公共部門的取得仍受到基礎設施和保險報銷限制的限制。在巴西，對比增強磁振造影技術在腫瘤學和神經病學成像領域的應用正在大規模大都會圈醫療保健系統中不斷擴展，這些系統由公立和私立機構組成。在英國，由於檢測能力有限，優先考慮的是資格標準、病人安全篩檢和標準化的放射學管治。德國擁有成熟的磁振造影生態系統，嚴格遵守臨床規範，擁有強大的專業成像能力，並充分考慮監管安全證據。在法國，醫院和門診機構正在系統性地使用造影劑，並專注於藥物安全監測和病患風險管理。在俄羅斯，大規模都市區醫院和專科醫療中心對MRI造影劑的需求仍然強勁，但採購和物流狀況可能會影響產品的供應。在義大利和西班牙，腫瘤學、肝臟影像、乳房MRI和神經影像領域已廣泛應用造影劑，這得益於強大的放射學專業群體和區域醫療保健系統的支持。在中國，隨著醫院容量的擴大、癌症診斷項目的推進以及高階影像設備的引進，主要省份使用造影劑的MRI應用正在增加。在印度，私立診斷中心、腫瘤醫院和都市區專科醫療機構的需求正在成長，但價格和可及性仍然是重要的考慮因素。在日本，MRI的應用非常成熟，人口老化導致診斷需求不斷成長，並且高度重視高品質的神經影像、肝臟影像以及安全至上的臨床方案。在澳大利亞，成熟的放射學標準與腫瘤科、神經科和當地轉診網路的需求相結合，推動了MRI的發展。同時，韓國的特點是醫院擁有先進的影像技術，積極採用新技術，以及造影磁振造影技術先進。

為行業領導者提供的實用建議

行業領導者應優先考慮基於證據的差異化，加強在安全性、診斷性能、穩定性以及高風險人群（特別是腎功能不全患者、兒童患者、老年患者和需要重複MRI掃描的患者）中的應用方面的臨床數據。產品策略應與市場對大環钆對比造影的持續偏好、最佳化劑量、清晰的標籤以及與最新MRI方案的兼容性保持一致。銷售團隊應透過提供正確使用方法、不利事件記錄、造影劑反應準備和工作流程整合的培訓來支援放射科，而不是僅依賴產品推廣。供應鏈管理人員應確保採購、包裝、品質保證和分銷環節的冗餘，以降低醫院和門診影像網路供不應求的風險。數位化整合也至關重要。造影相關人員應與影像資訊學團隊合作，實現可追溯性、電子篩檢、自動記錄和藥物警戒報告。最後，領導者需要密切關注不斷變化的環境預期，特別是關於钆排放的要求，支持負責任的廢棄物管理，並為日益強調永續性、透明度和長期安全管理的採購標準做好準備。

調查方法

本執行摘要採用系統化的二手調查方法編寫，重點關注檢驗、公開且有資料支持的資訊來源。分析利用了監管公告、處方資訊、放射學會指南、同行評審的臨床文獻、醫院實踐標準、藥物安全監測參考資料、疾病負擔公共衛生數據以及與造影造影 (MRI) 使用相關的醫療基礎設施指標。評估從臨床應用、安全性、法規環境、影像工作流程、區域應用以及整個醫療系統應用促進因素等方面對 MRI 造影劑進行評估。採用定性綜合分析來辨識方向轉變，不提供市場規模估算、市場規模計算、市場佔有率或預測。透過已記錄的醫療服務能力、政策方向、疾病負擔、影像基礎設施成熟度和臨床管治實踐來解讀區域、群體和國家層面的具體見解。調查方法強調對可靠資訊來源進行檢驗、排除未經證實的說法，並優先考慮與放射學、採購、臨床運營和生命科學戰略決策者相關的見解。

結論

造影造影（MRI）造影劑在現代診斷影像中仍然至關重要，尤其是在臨床上需要提高病灶檢出率、血管特徵分析、組織灌注評估和治療監測等方面。受以下因素驅動，業界正朝著更安全、更具選擇性和可追溯性的造影劑方向發展：對大環造影造影的偏好、腎臟風險篩檢、對钆殘留的日益關注、監管力度加大以及醫院採購標準的不斷完善。人工智慧、先進的MRI方案和數位放射線系統正在進一步重新定義造影增強成像的適用性、應用、解讀和監測方式。不同地區的趨勢差異顯著，成熟市場更注重管治和安全文檔，而新興市場則專注於擴展基礎設施和普及先進診斷技術。對於行業相關人員，成功的關鍵在於將穩定的供應、臨床證據、工作流程支援、數位整合和環境責任相結合。那些將MRI造影劑策略與患者安全、診斷可靠性和醫療系統效率相結合的機構，將更有能力滿足全球放射科醫生和患者不斷變化的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 MRI造影劑市場：依造影劑類型分類

  • 順磁性造影劑
    • 钆基造影劑
    • 錳基造影劑
  • 超順造影劑

第8章：MRI造影劑市場：依給藥途徑分類

  • 靜脈
  • 口服

第9章：MRI造影劑市場：依化學結構分類

  • 大環
  • 線性

第10章：MRI造影劑市場：依患者類型分類

  • 兒童
  • 成人
  • 老年人

第11章 MRI造影劑市場：依應用領域分類

  • 神經病學
    • 腦腫瘤
    • 多發性硬化症
    • 卒中/灌注成像
    • 腦下垂體影像
  • 肌肉骨骼系統
    • 關節影像診斷
    • 骨腫瘤
    • 發炎性關節炎
  • 心血管系統
  • 腫瘤學
  • 消化器官系統
    • 腸道造影/腸道造影檢查
    • 腸壁評估

第12章 MRI造影劑市場：依最終用途分類

  • 門診手術中心
  • 診斷和影像中心
  • 醫院
  • 研究機構

第13章 MRI造影劑市場：依通路分類

  • 離線
  • 線上

第14章 MRI造影劑市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 中東
  • 非洲

第15章 MRI造影劑市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第16章 MRI造影劑市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 德國
  • 印度
  • 英國
  • 法國
  • 韓國
  • 澳洲
  • 義大利
  • 加拿大
  • 巴西
  • 西班牙
  • 俄羅斯
  • 墨西哥

第17章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Bayer AG
  • Bracco Imaging SpA
  • GE HealthCare Technologies Inc.
  • Guerbet SA
  • Lantheus Holdings, Inc.
  • JB Chemicals & Pharmaceuticals Ltd.
  • Beijing Beilu Pharmaceutical Co., Ltd.
  • SANOCHEMIA Pharmazeutika GmbH
  • Unijules Life Sciences Ltd.
  • Biophore India Pharmaceuticals Pvt. Ltd.
  • Jodas Expoim Pvt. Ltd.
  • Leriva SA
  • BioPAL, Inc.
  • Accelius Global
  • Fresenius Kabi AG
  • FUJIFILM Wako Pure Chemical Corporation
  • Genetek Lifesciences Pvt. Ltd.
  • Hikma Pharmaceuticals PLC
  • iMAX Diagnostic Imaging Limited
  • Livealth Biopharma Pvt. Ltd.
  • Maya Biotech Pvt. Ltd.
  • Pharmika India pvt LTD.
  • Polarean Inc.
  • Rege Imaging & Cine Films（P）Ltd.
  • Reveal Pharmaceuticals
  • Spago Nanomedical AB
  • Subhra Pharma Private Limited
  • Taejoon Pharm Co., Ltd.
  • Trivitron Healthcare
Product Code: MRR-F927BA46208C

The MRI Contrast Media Agents Market is projected to grow by USD 252.76 million at a CAGR of 7.36% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 153.66 million
Estimated Year [2026] USD 164.31 million
Forecast Year [2032] USD 252.76 million
CAGR (%) 7.36%

MRI Contrast Media Agents Executive Summary

MRI contrast media agents are specialized diagnostic imaging products used to enhance tissue visualization in magnetic resonance imaging, particularly for the brain, spine, liver, breast, cardiovascular system, musculoskeletal structures, and oncologic assessment. The category is shaped by the clinical value of gadolinium-based contrast agents, organ-specific formulations, evolving macrocyclic and linear chelate preferences, and rising attention to patient safety in populations with renal impairment, pregnancy considerations, pediatric needs, and repeated imaging requirements. Demand is closely linked to the global burden of cancer, neurological disorders, cardiovascular disease, inflammatory conditions, and complex surgical planning, all of which rely on high-quality contrast-enhanced MRI for lesion characterization, staging, therapy monitoring, and differential diagnosis. Regulatory agencies and professional radiology bodies continue to emphasize appropriate use, dose optimization, documentation of prior exposure, and risk screening for nephrogenic systemic fibrosis and gadolinium retention. As healthcare systems expand access to advanced imaging, stakeholders across hospitals, diagnostic centers, outpatient imaging networks, and specialty clinics are prioritizing contrast agents that combine diagnostic confidence, safety evidence, supply reliability, workflow efficiency, and compatibility with modern MRI protocols.

Transformative Shifts in the MRI Contrast Media Landscape

The MRI contrast media agents landscape is undergoing significant transformation as imaging practice shifts from broad contrast utilization toward precision-guided, risk-adjusted administration. Radiology departments are increasingly standardizing protocols around macrocyclic gadolinium-based agents due to their higher kinetic stability compared with many linear agents, while also adopting structured screening for kidney function, allergy history, prior contrast reactions, and cumulative gadolinium exposure. Another major shift is the movement toward lower-dose and targeted imaging protocols supported by higher-field MRI systems, optimized pulse sequences, and improved image reconstruction techniques. Clinical adoption is also influenced by the expansion of outpatient imaging, integrated cancer care pathways, stroke and neurovascular imaging, liver lesion characterization, and cardiac MRI applications. At the same time, sustainability and procurement resilience are becoming more prominent, as healthcare providers seek stable supply chains, transparent quality controls, and products aligned with pharmacovigilance requirements. The competitive basis for MRI contrast media is therefore evolving beyond product availability to encompass safety profile, evidence depth, protocol adaptability, regulatory compliance, packaging efficiency, and integration into digital radiology workflows.

Cumulative Impact of Artificial Intelligence on MRI Contrast Media

Artificial intelligence is creating a cumulative impact across the MRI contrast media agents ecosystem by improving how contrast-enhanced MRI is planned, acquired, interpreted, and audited. AI-enabled protocol selection can support radiology teams in choosing appropriate contrast use based on indication, prior imaging, renal status, and clinical history, helping reduce unnecessary administration while preserving diagnostic quality. Image reconstruction and denoising algorithms are enabling clearer visualization from accelerated MRI acquisitions and may support dose-conscious imaging strategies when validated within clinical governance frameworks. In interpretation, AI tools can assist with lesion detection, segmentation, enhancement quantification, perfusion assessment, and longitudinal comparison in oncology, neurology, breast imaging, cardiac imaging, and liver imaging. AI also strengthens operational oversight by flagging incomplete safety documentation, tracking repeat exposure, supporting adverse event monitoring, and improving scheduling efficiency for contrast-dependent examinations. The greatest near-term value is expected from AI used as a decision-support and workflow-quality layer rather than a replacement for radiologist judgment, particularly where institutions require traceability, regulatory compliance, explainability, and clinically validated performance across diverse scanners and patient populations.

Key Regional Insights for MRI Contrast Media Agents

Asia-Pacific is characterized by rapid expansion of advanced diagnostic imaging capacity, growing cancer and cardiovascular screening needs, and increasing investments in tertiary hospitals and private diagnostic networks, with China, India, Japan, South Korea, and Australia contributing to diverse patterns of MRI contrast media utilization. North America remains highly protocol-driven, with strong adoption of safety screening, electronic health record integration, and guideline-based contrast administration across hospital and outpatient imaging settings in the United States and Canada. Europe is shaped by rigorous pharmacovigilance, environmental scrutiny, and harmonized clinical guidance, with many institutions emphasizing macrocyclic agent use, documentation of gadolinium exposure, and standardized consent workflows across mature healthcare systems. Latin America demonstrates rising use of contrast-enhanced MRI in oncology, neurology, and abdominal imaging, supported by expanding private healthcare access in major urban centers, although reimbursement variability and uneven scanner distribution influence access. The Middle East is advancing MRI capabilities through hospital modernization, medical tourism, and specialist centers in oncology, cardiology, and neurology, particularly across high-income Gulf economies. Africa presents a more heterogeneous environment, where MRI contrast media adoption is concentrated in major urban hospitals and academic centers, while infrastructure constraints, specialist availability, import dependence, and affordability remain key factors influencing utilization.

Key Group Insights for MRI Contrast Media Agents

ASEAN markets are seeing greater adoption of contrast-enhanced MRI as public and private healthcare systems upgrade imaging infrastructure, with demand linked to oncology, neuroimaging, hepatobiliary assessment, and urban diagnostic center growth. The GCC is distinguished by advanced hospital investment, high use of specialty imaging services, and strong demand for reliable procurement, regulatory quality, and premium diagnostic workflows across tertiary and quaternary care facilities. The European Union plays a central role in shaping MRI contrast media standards through stringent medicine regulation, post-market surveillance, environmental risk evaluation, and guideline-driven clinical practice that supports consistent safety documentation. BRICS countries collectively represent a broad spectrum of imaging maturity, with large patient populations, expanding tertiary care, and increasing local emphasis on affordability, supply security, and access to advanced diagnostics. G7 countries generally demonstrate mature MRI utilization, strong radiology governance, established reimbursement frameworks, and high sensitivity to evidence on gadolinium retention, renal safety, and risk-benefit assessment. NATO member countries, while diverse in healthcare structure, share a strong focus on resilient medical supply chains, hospital readiness, and advanced diagnostic capabilities, which supports demand for dependable MRI contrast media procurement and standardized safety protocols.

Key Country Insights for MRI Contrast Media Agents

The United States leads in protocolized contrast-enhanced MRI adoption across oncology, neurology, breast, cardiac, and musculoskeletal imaging, supported by extensive outpatient imaging networks and detailed safety documentation practices. Canada emphasizes guideline-based use, renal risk assessment, and equitable access across provincial healthcare systems, with major urban centers driving advanced MRI applications. Mexico is expanding contrast-enhanced MRI use through private hospitals and diagnostic chains, while public-sector access remains influenced by infrastructure and reimbursement constraints. Brazil shows growing utilization in oncology and neurological imaging across large metropolitan health systems, supported by a mix of public and private providers. The United Kingdom prioritizes appropriateness criteria, patient safety screening, and standardized radiology governance within a capacity-constrained imaging environment. Germany has a mature MRI ecosystem with strong clinical protocol adherence, robust specialty imaging, and attention to regulatory safety evidence. France demonstrates structured contrast use in hospital and outpatient settings, with emphasis on pharmacovigilance and patient risk management. Russia maintains demand for MRI contrast media across large urban hospitals and specialist centers, though procurement and logistics can influence product availability. Italy and Spain both show established use in oncology, liver imaging, breast MRI, and neuroimaging, supported by strong specialist radiology communities and regional healthcare systems. China is increasing contrast-enhanced MRI utilization as hospital capacity, cancer diagnosis programs, and high-end imaging installations expand across major provinces. India is experiencing rising demand through private diagnostic centers, oncology hospitals, and urban specialty care, while affordability and access remain important considerations. Japan has highly advanced MRI adoption, aging-population-driven diagnostic needs, and strong emphasis on high-quality neuroimaging, liver imaging, and safety-oriented clinical protocols. Australia combines mature radiology standards with demand from oncology, neurology, and rural referral networks, while South Korea demonstrates advanced hospital-based imaging, strong technology adoption, and high procedural sophistication in contrast-enhanced MRI.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based differentiation by strengthening clinical data on safety, diagnostic performance, stability, and use in high-risk populations, particularly patients with impaired renal function, pediatric patients, older adults, and individuals requiring repeated MRI examinations. Product strategy should align with the ongoing preference for macrocyclic gadolinium-based agents, dose optimization, clear labeling, and compatibility with modern MRI protocols. Commercial teams should support radiology departments with education on appropriate use, adverse event documentation, contrast reaction preparedness, and workflow integration rather than relying only on product promotion. Supply chain leaders should build redundancy in sourcing, packaging, quality assurance, and distribution to reduce the risk of shortages in hospital and outpatient imaging networks. Digital integration is also essential: contrast media stakeholders should collaborate with imaging informatics teams to enable traceability, electronic screening, automated documentation, and pharmacovigilance reporting. Finally, leaders should monitor evolving environmental expectations related to gadolinium discharge, support responsible waste management, and prepare for procurement criteria that increasingly consider sustainability, transparency, and long-term safety stewardship.

Research Methodology

This executive summary is developed through a structured secondary research methodology focused on verified, publicly available, and data-backed sources. The analysis draws on regulatory communications, prescribing information, radiology society guidelines, peer-reviewed clinical literature, hospital practice standards, pharmacovigilance references, public health data on disease burden, and healthcare infrastructure indicators relevant to MRI utilization. The assessment evaluates MRI contrast media agents by clinical application, safety profile, regulatory context, imaging workflow, regional access conditions, and adoption drivers across healthcare systems. Qualitative synthesis is used to identify directional shifts without presenting market estimation, market sizing, market share, or forecasting. Regional, group, and country insights are interpreted through documented healthcare capacity, policy orientation, disease burden, imaging infrastructure maturity, and clinical governance practices. The methodology emphasizes triangulation of credible sources, exclusion of unsupported claims, and prioritization of findings that are relevant to decision-makers in radiology, procurement, clinical operations, and life sciences strategy.

Conclusion

MRI contrast media agents remain essential to modern diagnostic imaging, particularly where enhanced lesion detection, vascular characterization, tissue perfusion assessment, and treatment monitoring are clinically required. The industry is moving toward safer, more selective, and more traceable contrast use, shaped by macrocyclic agent preference, renal risk screening, gadolinium retention awareness, regulatory oversight, and evolving hospital procurement standards. Artificial intelligence, advanced MRI protocols, and digital radiology systems are further redefining how contrast examinations are justified, performed, interpreted, and monitored. Regional dynamics vary significantly, with mature markets emphasizing governance and safety documentation, while emerging markets focus on infrastructure expansion and access to advanced diagnostics. For industry participants, success will depend on combining reliable supply, clinical evidence, workflow support, digital integration, and environmental responsibility. Organizations that align MRI contrast media strategies with patient safety, diagnostic confidence, and health system efficiency will be best positioned to meet the changing needs of radiology providers and patients worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. MRI Contrast Media Agents Market, by Agent Type

  • 7.1. Introduction
  • 7.2. Paramagnetic Contrast Agents
    • 7.2.1. Gadolinium-based Contrast Agents
    • 7.2.2. Manganese-based Contrast Agents
  • 7.3. Superparamagnetic Contrast Agents

8. MRI Contrast Media Agents Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. MRI Contrast Media Agents Market, by Chemical Structure

  • 9.1. Introduction
  • 9.2. Macrocyclic
  • 9.3. Linear

10. MRI Contrast Media Agents Market, by Patient Type

  • 10.1. Introduction
  • 10.2. Pediatric
  • 10.3. Adult
  • 10.4. Geriatric

11. MRI Contrast Media Agents Market, by Application

  • 11.1. Introduction
  • 11.2. Neurology
    • 11.2.1. Brain Tumors
    • 11.2.2. Multiple Sclerosis
    • 11.2.3. Stroke / Perfusion Imaging
    • 11.2.4. Pituitary Imaging
  • 11.3. Musculoskeletal
    • 11.3.1. Joint Imaging
    • 11.3.2. Bone Tumor
    • 11.3.3. Inflammatory Arthritis
  • 11.4. Cardiovascular
  • 11.5. Oncology
  • 11.6. Gastrointestinal
    • 11.6.1. Enteroclysis / Enterography
    • 11.6.2. Bowel Wall Assessment

12. MRI Contrast Media Agents Market, by End Use

  • 12.1. Introduction
  • 12.2. Ambulatory Surgical Centers
  • 12.3. Diagnostic & Imaging Centers
  • 12.4. Hospitals
  • 12.5. Research Institutes

13. MRI Contrast Media Agents Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Offline
  • 13.3. Online

14. MRI Contrast Media Agents Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. Europe
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Middle East
  • 14.6. Africa

15. MRI Contrast Media Agents Market, by Group

  • 15.1. NATO
  • 15.2. G7
  • 15.3. BRICS
  • 15.4. European Union
  • 15.5. ASEAN
  • 15.6. GCC

16. MRI Contrast Media Agents Market, by Country

  • 16.1. China
  • 16.2. United States
  • 16.3. Japan
  • 16.4. Germany
  • 16.5. India
  • 16.6. United Kingdom
  • 16.7. France
  • 16.8. South Korea
  • 16.9. Australia
  • 16.10. Italy
  • 16.11. Canada
  • 16.12. Brazil
  • 16.13. Spain
  • 16.14. Russia
  • 16.15. Mexico

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. FPNV Positioning Matrix, 2025
  • 17.3. Market Concentration Analysis, 2025
    • 17.3.1. Concentration Ratio (CR)
    • 17.3.2. Herfindahl Hirschman Index (HHI)
  • 17.4. Recent Developments & Impact Analysis, 2025
  • 17.5. Product Portfolio Analysis, 2025
  • 17.6. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Bayer AG
  • 18.2. Bracco Imaging S.p.A.
  • 18.3. GE HealthCare Technologies Inc.
  • 18.4. Guerbet SA
  • 18.5. Lantheus Holdings, Inc.
  • 18.6. J.B. Chemicals & Pharmaceuticals Ltd.
  • 18.7. Beijing Beilu Pharmaceutical Co., Ltd.
  • 18.8. SANOCHEMIA Pharmazeutika GmbH
  • 18.9. Unijules Life Sciences Ltd.
  • 18.10. Biophore India Pharmaceuticals Pvt. Ltd.
  • 18.11. Jodas Expoim Pvt. Ltd.
  • 18.12. Leriva SA
  • 18.13. BioPAL, Inc.
  • 18.14. Accelius Global
  • 18.15. Fresenius Kabi AG
  • 18.16. FUJIFILM Wako Pure Chemical Corporation
  • 18.17. Genetek Lifesciences Pvt. Ltd.
  • 18.18. Hikma Pharmaceuticals PLC
  • 18.19. iMAX Diagnostic Imaging Limited
  • 18.20. Livealth Biopharma Pvt. Ltd.
  • 18.21. Maya Biotech Pvt. Ltd.
  • 18.22. Pharmika India pvt LTD.
  • 18.23. Polarean Inc.
  • 18.24. Rege Imaging & Cine Films (P) Ltd.
  • 18.25. Reveal Pharmaceuticals
  • 18.26. Spago Nanomedical AB
  • 18.27. Subhra Pharma Private Limited
  • 18.28. Taejoon Pharm Co., Ltd.
  • 18.29. Trivitron Healthcare

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 27. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PARAMAGNETIC CONTRAST AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PARAMAGNETIC CONTRAST AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PARAMAGNETIC CONTRAST AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GADOLINIUM-BASED CONTRAST AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GADOLINIUM-BASED CONTRAST AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GADOLINIUM-BASED CONTRAST AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MANGANESE-BASED CONTRAST AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MANGANESE-BASED CONTRAST AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MANGANESE-BASED CONTRAST AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SUPERPARAMAGNETIC CONTRAST AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SUPERPARAMAGNETIC CONTRAST AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SUPERPARAMAGNETIC CONTRAST AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MACROCYCLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MACROCYCLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MACROCYCLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LINEAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LINEAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LINEAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STROKE / PERFUSION IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STROKE / PERFUSION IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STROKE / PERFUSION IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PITUITARY IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PITUITARY IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PITUITARY IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MUSCULOSKELETAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MUSCULOSKELETAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MUSCULOSKELETAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL JOINT IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL JOINT IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL JOINT IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BONE TUMOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BONE TUMOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BONE TUMOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFLAMMATORY ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFLAMMATORY ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFLAMMATORY ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GASTROINTESTINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENTEROCLYSIS / ENTEROGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENTEROCLYSIS / ENTEROGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENTEROCLYSIS / ENTEROGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BOWEL WALL ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BOWEL WALL ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BOWEL WALL ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIAGNOSTIC & IMAGING CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIAGNOSTIC & IMAGING CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIAGNOSTIC & IMAGING CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 182. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 187. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 192. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 198. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 199. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 246. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 247. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 248. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. JAPAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 277. JAPAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. JAPAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 279. JAPAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. JAPAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. JAPAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. JAPAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 283. JAPAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 284. JAPAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 285. JAPAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 296. GERMANY MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 297. GERMANY MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 305. INDIA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. INDIA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 307. INDIA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 308. INDIA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 309. INDIA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED KINGDOM MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED KINGDOM MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED KINGDOM MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED KINGDOM MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED KINGDOM MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED KINGDOM MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED KINGDOM MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED KINGDOM MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED KINGDOM MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED KINGDOM MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 325. FRANCE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 326. FRANCE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 327. FRANCE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. FRANCE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 329. FRANCE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 330. FRANCE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 331. FRANCE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 332. FRANCE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 333. FRANCE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 334. SOUTH KOREA MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. SOUTH KOREA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. SOUTH KOREA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PARAMAGNETIC CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 337. SOUTH KOREA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 338. SOUTH KOREA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CHEMICAL STRUCTURE, 2018-2032 (USD MILLION)
  • TABLE 339. SOUTH KOREA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. SOUTH KOREA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MIL